Atrium Health Levine Cancer | Strategic Alliance Partners

Matthew C. Ward, MD, discusses considerations for salvage radiation therapy in prostate cancer.

Earle Burgess, MD, discusses the FDA accelerated approval of rucaparib in BRCA-positive metastatic castration-resistant prostate cancer.

Matthew C. Ward, MD, discusses the debate over adjuvant radiation therapy in prostate cancer.

Saad Z. Usmani, MD, FACP, discusses treatment considerations for patients with multiple myeloma who are in their second relapse or beyond.

Earle Burgess, MD, discusses treatment considerations for PARP inhibitor use in patients with prostate cancer.

Saad Z. Usmani, MD, FACP, discusses optimizing treatment selection in relapsed/refractory multiple myeloma.

Saad Z. Usmani, MD, FACP, discusses the rapidly changing cellular therapy paradigm in relapsed/refractory multiple myeloma.

Nilanjan Ghosh, MD, PhD, discusses the potential advantages of moving CAR T-cell therapy into the frontline setting for patients with diffuse large B-cell lymphoma.

Dr. Coleman and Dr. Brown discuss how understandings of BRCA and patient eligibility for PARP inhibitors have evolved in ovarian cancer, the effects of frontline maintenance trials on treatment recommendations, the clinical significance of the findings from the ARIEL4 trial, and where PARP inhibition is headed in the field.

Saad Z. Usmani, MD, FACP, discusses the potential utility of allogeneic CAR T-cell therapy in multiple myeloma.

Jason Zhu, MD, discusses several approaches under exploration in the treatment of patients with previously treated, locally advanced, or metastatic urothelial carcinoma.

Claud N. Grigg, MD, highlights different frontline combination regimens that are improving outcomes for patients with metastatic renal cell carcinoma.

During the question-and-answer portion of the virtual Institutional Perspectives in Cancer webinar, Earle Burgess, MD, and colleagues provide insight into how they are navigating the evolving treatment landscape of renal cell carcinoma and bladder cancer.

Justin T. Matulay, MD, discusses whether there is a role for cytoreductive nephrectomy in metastatic renal cell carcinoma, as well as key data that have helped guide this paradigm.

Allison M. Puechl, MD, discusses choosing between PARP inhibitors in ovarian cancer.

Erin K. Crane, MD, MPH, discusses the benefit of maintenance PARP inhibitors in ovarian cancer.

Jubilee Brown, MD, discusses the utility of minimally invasive surgery in ovarian cancer.

R. Wendel Naumann, MD, discusses numerous investigations of PD-1 inhibitors in combination with PARP inhibitors or other targeted agents, as well as chemotherapy, and how it could finally start the next chapter of immunotherapy in gynecologic malignancies.

Allison M. Puechl, MD, discusses the role of second-line maintenance therapy in patients with recurrent ovarian cancer and considerations that may limit the accessibility of PARP inhibitors in this space.

Nilanjan Ghosh, MD, PhD, director of the Lymphoma Program and a physician with Levine Cancer Institute, discusses unmet needs with CAR T-cell therapy in diffuse large B-cell lymphoma.

Saad Z. Usmani, MD, FACP, discusses the significance of the FDA approval of daratumumab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma who have received at least 1 previous line of therapy.

In our exclusive interview, Saad Z. Usmani, MD, FACP, discusses the FDA approval of daratumumab, carfilzomib, and dexamethasone in relapsed/refractory multiple myeloma.

In our exclusive interview, Antoinette R. Tan, MD, of Atrium Health, discusses the FDA approval of the fixed-dose combination of pertuzumab and trastuzumab in HER2-positive breast cancer and highlights the results of the pivotal FeDeriCa trial.

Nilanjan Ghosh, MD, PhD, discusses remaining questions with BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Saad ​Z. Usmani, MD, FACP, discusses the key takeaways from the randomized phase 2 SWOG 1211 trial in patients with newly diagnosed, high-risk multiple myeloma.

R. Wendel Naumann, MD, discusses the early results reported with STRO-002, the hope for this agent in the ovarian cancer space, and the next steps for this research.

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

R. Wendel Naumann, MD, discusses the FDA approval of niraparib in ovarian cancer and the impact on the current treatment paradigm.

Peter Voorhees, MD, discusses the evolution of idecabtagene vicleucel (ide-cel; bb2121) in the phase 2 KarMMa study in relapsed/refractory multiple myeloma.